Search results
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
The Wall Street Journal· 5 days agoA deputy was calling with good news: The company’s new, experimental drug tirzepatide not only cut...
Gateway - Quartz
Quartz· 1 hour agoChase’s asset management division just finished raising a $500 million biotech fund, and its managers are looking at weight loss drug ...
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity ...
Motley Fool via Yahoo Finance· 5 days ago/Mounjaro could achieve greater weight loss. This efficacy advantage could enable Lilly's weight-...
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It
The Motley Fool via AOL· 4 days agoIt was a phase-one trial but an encouraging one nonetheless. AstraZeneca has shown interest in the...
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Motley Fool via Yahoo Finance· 4 days agoAlpine's porvetacicept should advance into phase 3 testing for treating the rare kidney disease IgA...
Takeda drug for rare types of epilepsy misses goal in late-stage trial
BioPharma Dive via Yahoo Finance· 2 days agoCalled soticlestat, the drug had seemed promising in earlier studies for people with Dravet and...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 6 days agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
Motley Fool via Yahoo Finance· 2 days agoThe biggest story for Viking was its announcement in late February of results from a phase 2 study...
Five S&P 500 Stocks To Watch In Today's Market; Eli Lilly Reaches New High After Drug News
Investor's Business Daily· 7 days agoBerkshire stock's up/down volume ratio of 1.3 shows renewed interest for shares over the last 50...
Why 93% Of This Biotech's Value Just Went Up In Smoke
Investor's Business Daily· 1 day agoWedbush analyst Laura Chico slashed her price target on Aerovate stock to 3 from 41, calling the...
